Recombinant human insulin - Aventis

Drug Profile

Recombinant human insulin - Aventis

Alternative Names: HR 1799; insulin HPR; Insulin Human Winthrop; Insulin Human Winthrop - Sanofi-aventis; Insuman; Insuman Comb 25

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 23 Mar 2015 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus in China (SC)
  • 25 Jul 2013 Preregistration for Type-1 diabetes mellitus in European Union (Intraperitoneal) before July 2013
  • 25 Jul 2013 The CHMP recommends approval of Recombinant human insulin (Intraperitoneal) for Type-1 diabetes mellitus in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top